Carcinoid Syndrome News and Research

RSS
Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon presents six posters on LX4211 at ADA meeting

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon receives FDA Orphan Drug designation for telotristat etiprate to treat carcinoid syndrome

Lexicon completes rights offering

Lexicon completes rights offering

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon's LX4211 clinical data presented at EASD annual meeting

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon's second quarter revenues decrease 55% to $0.6 million

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

First Worldwide NET Cancer Awareness Day on November 10, 2010

First Worldwide NET Cancer Awareness Day on November 10, 2010